\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ focal\\ neurologic\\ deficits\\.\ \(1\)\
\-\ this\\ patient\\ had\\ an\\ incidental\\ mass\\ found\\ on\\ a\\ head\\ ct\\ after\\ a\\ fall\\.\\ \\ he\\ has\\ no\\ history\\ of\\ seizures\\ or\\ focal\\ neurologic\\ deficits\\.\\ \\ the\\ patient\\ elected\\ to\\ have\\ a\\ gross\\ total\\ resection\\ of\\ the\\ mass\\.\\ \\ he\\ continues\\ to\\ be\\ free\\ of\\ seizures\\ and\\ focal\\ neurologic\\ deficits\\ at\\ one\\ month\\ post\\-op\\.\ \(0\)\
\-\ right\\ frontal\\ lobe\\ lesion\\ without\\ midline\\ shift\\ or\\ sulcal\\ effacement\\,\\ measuring\\ 3\\.5\\ x\\ 2\\.9\\ x\\ 3\\.0\\ cm\\.\\ \\ on\\ ct\\,\\ the\\ lesion\\ low\\ attenuation\\ compared\\ \\ to\\ brain\\.\\ \\ on\\ mri\\,\\ it\\ has\\ corresponding\\ low\\ signal\\ on\\ t1\\ and\\ high\\ on\\ t2\\.\\ \\ there\\ is\\ no\\ post\\-contrast\\ enhancement\\ and\\ demonstrates\\ no\\ suppression\\ on\\ flair\\.\ \(0\)\
\-\ diffuse\\ astrocytoma\\ who\\ gr\\ 2\ \(0\)\
\-\ \\â\\€\\¢\\ diffuse\\ astrocytoma\\ \\(gr\\ 2\\ or\\ gr\\ 3\\)\ \(0\)\
\-\ \\â\\€\\¢\\ pleomorphic\\ xanthoastrocytoma\\ \\(pxa\\)\ \(0\)\
\-\ \\â\\€\\¢\\ pilocytic\\ astrocytoma\ \(1\)\
\-\ \\â\\€\\¢\\ anaplastic\\ astrocytoma\ \(0\)\
\-\ \\â\\€\\¢\\ dnet\\ \\(dysembryoplastic\\ neuroepithelial\\ tumor\\)\ \(0\)\
\-\ \\â\\€\\¢\\ neurocysticercosis\ \(0\)\
\-\ \\â\\€\\¢\\ metastasis\ \(6\)\
\-\ this\\ patient\\ is\\ a\\ 35\\ year\\ old\\ man\\ who\\ presents\\ after\\ a\\ fall\\.\\ \\ he\\ has\\ no\\ history\\ of\\ seizures\\ or\\ focal\\ neurologic\\ deficits\\.\ \(0\)\
\-\ diffuse\\ astrocytomas\\ are\\ grade\\ 2\\ astrocytic\\ tumors\\ according\\ to\\ the\\ who\\ classification\\ of\\ cns\\ masses\\ \\(1\\)\\.\\ \\ they\\ often\\ present\\ in\\ the\\ 4th\\-5th\\ decade\\ of\\ life\\ \\(2\\)\\,\\ with\\ most\\ being\\ found\\ in\\ the\\ frontal\\ lobe\\ \\(40\\%\\)\\ \\(3\\)\\.\\ \\ patients\\ typically\\ present\\ late\\ and\\ have\\ a\\ history\\ of\\ seizures\\.\\ \\ on\\ mri\\,\\ these\\ lesions\\ are\\ typically\\ bright\\ on\\ t2\\,\\ but\\ do\\ not\\ enhance\\ and\\ do\\ not\\ suppress\\ on\\ flair\\.\\ \\ occasionally\\,\\ high\\ t2\\ intensity\\ can\\ be\\ see\\ surrounding\\ the\\ lesion\\.\\ \\ this\\ represents\\ infiltration\\ of\\ the\\ astrocytoma\\,\\ but\\ it\\ can\\ be\\ mistaken\\ for\\ edema\\.\ \(0\)\
\-\ these\\ neoplasms\\ have\\ a\\ variable\\ course\\,\\ with\\ some\\ progressing\\ malignantly\\ to\\ higher\\ grade\\ gliomas\\ \\(anaplastic\\ or\\ gbms\\)\\.\\ \\ indicators\\ that\\ confer\\ better\\ prognostic\\ include\\:\\ higher\\ degree\\ of\\ function\\ on\\ the\\ kps\\ scale\\ \\(\\>80\\)\\,\\ location\\ of\\ the\\ lesion\\ in\\ non\\-eloquent\\ locations\\,\\ size\\ of\\ the\\ lesion\\ less\\ than\\ 4cm\\,\\ and\\ age\\ less\\ than\\ 50\\ \\(2\\)\\.\\ \\ similar\\ patients\\ with\\ all\\ of\\ these\\ indicators\\ have\\ a\\ pre\\-op\\ 10\\ year\\ survival\\ of\\ 90\\%\\ \\(2\\)\\.\ \(0\)\
\-\ resection\\ of\\ these\\ lesions\\ is\\ controversial\\.\\ \\ pathologically\\,\\ these\\ lesions\\ are\\ often\\ infiltrative\\.\\ \\ \\ if\\ gross\\ total\\ resection\\ is\\ chosen\\ by\\ the\\ neurosurgeon\\ and\\ the\\ patient\\,\\ \\>50\\%\\ will\\ recur\\ in\\ 5\\ years\\ \\(4\\)\\.\ \(0\)\
\-\ mr\\ spectroscopy\ \(0\)\
\-\ in\\ some\\ cases\\,\\ it\\ may\\ be\\ difficult\\ to\\ determine\\ whether\\ or\\ not\\ an\\ abnormality\\ on\\ mri\\ represents\\ a\\ benign\\ or\\ malignant\\ lesion\\.\\ \\ proton\\ mr\\ spectroscopy\\ \\(mrs\\ or\\ 1hmrs\\)\\ can\\ be\\ a\\ useful\\ \\ adjunct\\ to\\ mri\\.\\ \\ mrs\\ uses\\ the\\ same\\ nuclear\\ magnetic\\ resonance\\ mechanisms\\ used\\ in\\ mri\\,\\ but\\ instead\\ of\\ creating\\ an\\ image\\,\\ it\\ creates\\ a\\ spectrum\\ representing\\ the\\ biochemical\\ composition\\ a\\ region\\ of\\ interest\\.\\ \\ lesions\\ have\\ unique\\ biochemical\\ signatures\\ that\\ can\\ assist\\ in\\ diagnosis\\.\ \(0\)\
\-\ normal\\ brain\\ tissue\\ has\\ major\\ peaks\\ for\\ the\\ molecules\\ myo\\-inositol\\,\\ choline\\,\\ creatinine\\,\\ and\\ n\\-acetylaspartate\\.\\ \\ on\\ the\\ spectra\\,\\ these\\ are\\ read\\ left\\ to\\ right\\,\\ and\\ generally\\ will\\ have\\ a\\ upward\\ angle\\ of\\ 45\\ degrees\\ \\(5\\)\\.\\ \\ this\\ angle\\ is\\ known\\ as\\ the\\ hunter\\â\\€\\™s\\ angle\\ \\(5\\)\\.\\ \\ the\\ angle\\ is\\ deranged\\ when\\ any\\ of\\ these\\ compounds\\ are\\ greater\\ or\\ less\\ than\\ normal\\,\\ and\\ this\\ can\\ indicate\\ pathology\\.\\ \\ \ \(0\)\
\-\ examining\\ these\\ peaks\\ closer\\,\\ choline\\ on\\ mrs\\ represents\\ cellular\\ turn\\ over\\,\\ while\\ n\\-acetylaspartate\\ represents\\ normal\\ neural\\ tissue\\ \\(5\\)\\.\\ \\ an\\ increase\\ of\\ choline\\ and\\ a\\ decrease\\ of\\ n\\-acetylaspartate\\ can\\ represent\\ neoplasia\\ \\(5\\)\\.\\ \\ elevated\\ lactate\\ can\\ be\\ seen\\ on\\ the\\ spectrum\\,\\ which\\ is\\ also\\ a\\ useful\\ indicator\\ for\\ neoplasia\\ \\(5\\)\\.\ \(0\)\
\-\ mrs\\ takes\\ experience\\ to\\ understand\\ and\\ interpret\\ correctly\\.\\ \\ certain\\ other\\ molecules\\ in\\ the\\ system\\ and\\ physiologic\\ states\\ can\\ make\\ mrs\\ more\\ complex\\.\\ \\ for\\ instance\\,\\ \\ the\\ neonatal\\ brain\\ can\\ look\\ similar\\ to\\ neoplasia\\ due\\ to\\ increased\\ cellular\\ turnover\\.\\ \\ additionally\\,\\ alcohol\\,\\ mannitol\\,\\ glucose\\,\\ and\\ many\\ common\\ medications\\ can\\ be\\ present\\ in\\ the\\ patient\\ and\\ the\\ region\\ of\\ interest\\,\\ changing\\ the\\ appearance\\ of\\ the\\ spectrum\\ with\\ their\\ unique\\ chemical\\ shifts\\ \\(5\\)\\.\\ \\ \ \(0\)\
\-\ unfortunately\\,\\ despite\\ 20\\ years\\ of\\ existence\\,\\ there\\ is\\ scant\\ research\\ in\\ this\\ aspect\\ of\\ mri\\,\\ despite\\ it\\ being\\ a\\ noninvasive\\ and\\ relatively\\ inexpensive\\ adjunct\\ to\\ mr\\ imaging\\ that\\ physicians\\ already\\ request\\ \\(5\\)\\.\\ \\ at\\ the\\ same\\ time\\,\\ small\\,\\ but\\ growing\\ utility\\ has\\ been\\ found\\ in\\ the\\ diagnosis\\ and\\ treatment\\ of\\ a\\ variety\\ of\\ pathologic\\ conditions\\ of\\ the\\ brain\\.\\ \\ some\\ research\\ has\\ also\\ been\\ conducted\\ in\\ various\\ other\\ tissues\\,\\ including\\ the\\ kidney\\,\\ liver\\,\\ and\\ breast\\,\\ but\\ more\\ research\\ is\\ into\\ this\\ technology\\ is\\ needed\\ to\\ improve\\ clinical\\ applicability\\.\ \(0\)\
\-\ \\-\\-\ \(461\)\
\-\ 1\\.\\ \\ louis\\ dn\\,\\ ohgaki\\ h\\,\\ et\\ al\\.\\ the\\ 2007\\ who\\ classification\\ of\\ tumours\\ of\\ the\\ central\\ nervous\\ system\\.\\ acta\\ neuropathol\\ 114\\(2\\)\\:\\ 97\\-109\\.\ \(0\)\
\-\ 2\\.\\ \\ chang\\ ef\\,\\ smith\\ js\\,\\ et\\ al\\.\\ preoperative\\ prognostic\\ classification\\ system\\ for\\ hemispheric\\ low\\-grade\\ gliomas\\ in\\ adults\\.\\ j\\ neurosurg\\ 109\\(5\\)\\:\\ 817\\-24\\.\ \(0\)\
\-\ 3\\.\\ \\ larjavaara\\ sr\\,\\ mantyla\\,\\ et\\ al\\.\\ \\ incidence\\ of\\ gliomas\\ by\\ anatomic\\ location\\.\\ neuro\\ oncol\\ 9\\(3\\)\\:\\ 319\\-25\\.\ \(0\)\
\-\ 4\\.\\ \\ shaw\\ eg\\,\\ berkey\\ b\\,\\ et\\ al\\.\\ recurrence\\ following\\ neurosurgeon\\-determined\\ gross\\-total\\ resection\\ of\\ adult\\ supratentorial\\ low\\-grade\\ glioma\\:\\ results\\ of\\ a\\ prospective\\ clinical\\ trial\\.\\ j\\ neurosurg\\ 109\\(5\\)\\:\\ 835\\-41\\.\ \(0\)\
\-\ 5\\.\\ \\ lin\\ a\\,\\ ross\\ bd\\,\\ et\\ al\\.\\ efficacy\\ of\\ proton\\ magnetic\\ resonance\\ spectroscopy\\ in\\ neurological\\ diagnosis\\ and\\ neurotherapeutic\\ decision\\ making\\.\\ neurorx\\ 2\\(2\\)\\:\\ 197\\-214\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ mrs\\:\\ 0\\.222009284430632\ \(0\)\
\-\ of\\:\\ 0\\.19404749940047458\ \(0\)\
\-\ the\\:\\ 0\\.1918601849033353\ \(0\)\
\-\ can\\:\\ 0\\.1576814905099004\ \(0\)\
\-\ these\\:\\ 0\\.1357440369652193\ \(0\)\
\-\ on\\:\\ 0\\.12704944422412107\ \(0\)\
\-\ choline\\:\\ 0\\.12225207843425906\ \(0\)\
\-\ al\\:\\ 0\\.11937411628393882\ \(0\)\
\-\ and\\:\\ 0\\.11797130613686596\ \(0\)\
\-\ et\\:\\ 0\\.11769104468984992\ \(0\)\
\-\ spectroscopy\\:\\ 0\\.1172196977720005\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.11341696073500897\ \(0\)\
\-\ gr\\:\\ 0\\.11034056265860388\ \(0\)\
\-\ 109\\:\\ 0\\.11034056265860388\ \(0\)\
\-\ neoplasia\\:\\ 0\\.10858291411948914\ \(0\)\
\-\ represents\\:\\ 0\\.10739766120138072\ \(0\)\
\-\ research\\:\\ 0\\.10556375439562331\ \(0\)\
\-\ angle\\:\\ 0\\.10542370194205976\ \(0\)\
\-\ in\\:\\ 0\\.10464894760041588\ \(0\)\
\-\ gliomas\\:\\ 0\\.10424611244198985\ \(0\)\
\-\ deficits\\:\\ 0\\.10330678131499126\ \(0\)\
\-\ seizures\\:\\ 0\\.09811510853369979\ \(0\)\
\-\ to\\:\\ 0\\.09765467889910635\ \(0\)\
\-\ neurologic\\:\\ 0\\.09604096977963657\ \(0\)\
\-\ or\\:\\ 0\\.09407794387045915\ \(0\)\
\-\ classification\\:\\ 0\\.09267283297989541\ \(0\)\
\-\ mri\\:\\ 0\\.09254333741571524\ \(0\)\
\-\ spectrum\\:\\ 0\\.09150173812515569\ \(0\)\
\-\ have\\:\\ 0\\.09006323433325533\ \(0\)\
\-\ molecules\\:\\ 0\\.08645288918286978\ \(0\)\
\-\ lesion\\:\\ 0\\.08643358765732546\ \(0\)\
\-\ grade\\:\\ 0\\.0864280173021054\ \(0\)\
\-\ be\\:\\ 0\\.08532442255124047\ \(0\)\
\-\ indicators\\:\\ 0\\.08453212563688543\ \(0\)\
\-\ has\\:\\ 0\\.08234983824385164\ \(0\)\
\-\ is\\:\\ 0\\.08228802280935413\ \(0\)\
\-\ biochemical\\:\\ 0\\.08150138562283937\ \(0\)\
\-\ gross\\:\\ 0\\.07999371360332591\ \(0\)\
\-\ peaks\\:\\ 0\\.07915056103345636\ \(0\)\
\-\ neurosurgeon\\:\\ 0\\.077229797487472\ \(0\)\
\-\ resection\\:\\ 0\\.07704419863380516\ \(0\)\
\-\ it\\:\\ 0\\.07690531998794181\ \(0\)\
\-\ adjunct\\:\\ 0\\.07560581504893064\ \(0\)\
\-\ brain\\:\\ 0\\.07492695046816172\ \(0\)\
\-\ interest\\:\\ 0\\.07487897289808898\ \(0\)\
\-\ neurosurg\\:\\ 0\\.07487897289808898\ \(0\)\
\-\ but\\:\\ 0\\.07429349345385501\ \(0\)\
\-\ total\\:\\ 0\\.07386116526514676\ \(0\)\
\-\ this\\:\\ 0\\.07227482757190862\ \(0\)\
\-\ focal\\:\\ 0\\.07189301417486342\ \(0\)\
\-\ prognostic\\:\\ 0\\.07037583626374887\ \(0\)\
\-\ cellular\\:\\ 0\\.0694974082946599\ \(0\)\
\-\ lesions\\:\\ 0\\.06902723757031495\ \(0\)\
\-\ low\\:\\ 0\\.0689664292590866\ \(0\)\
\-\ system\\:\\ 0\\.06877008575991987\ \(0\)\
\-\ who\\:\\ 0\\.0679876295557464\ \(0\)\
\-\ unique\\:\\ 0\\.06757664474867554\ \(0\)\
\-\ anaplastic\\:\\ 0\\.06595266231013419\ \(0\)\
\-\ proton\\:\\ 0\\.06536723211619086\ \(0\)\
\-\ resonance\\:\\ 0\\.06307350811433544\ \(0\)\
\-\ magnetic\\:\\ 0\\.06198645882095511\ \(0\)\
\-\ less\\:\\ 0\\.061326099291882374\ \(0\)\
\-\ found\\:\\ 0\\.0583269462505569\ \(0\)\
\-\ mr\\:\\ 0\\.0583269462505569\ \(0\)\
\-\ useful\\:\\ 0\\.05737609446593556\ \(0\)\
\-\ are\\:\\ 0\\.05700892382884938\ \(0\)\
\-\ some\\:\\ 0\\.05671740483688416\ \(0\)\
\-\ diffuse\\:\\ 0\\.0565311250895382\ \(0\)\
\-\ higher\\:\\ 0\\.05458134905036192\ \(0\)\
\-\ he\\:\\ 0\\.0533796697773602\ \(0\)\
\-\ despite\\:\\ 0\\.05229207302518567\ \(0\)\
\-\ t2\\:\\ 0\\.051862037413492296\ \(0\)\
\-\ flair\\:\\ 0\\.05112464006234447\ \(0\)\
\-\ than\\:\\ 0\\.05109978090823869\ \(0\)\
\-\ fall\\:\\ 0\\.050073766316522134\ \(0\)\
\-\ do\\:\\ 0\\.04981037678254303\ \(0\)\
\-\ patient\\:\\ 0\\.048865252667366806\ \(0\)\
\-\ no\\:\\ 0\\.04885606139820347\ \(0\)\
\-\ malignantly\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ kps\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ 1hmrs\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ signatures\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ spectra\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ deranged\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ applicability\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ neuropathol\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ larjavaara\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ mantyla\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ shaw\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ berkey\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ neurotherapeutic\\:\\ 0\\.048053020960833116\ \(0\)\
\-\ same\\:\\ 0\\.04753787993396654\ \(0\)\
\-\ diagnosis\\:\\ 0\\.046729745677140055\ \(0\)\
\-\ present\\:\\ 0\\.04625555187942119\ \(0\)\
\-\ an\\:\\ 0\\.04596075670496636\ \(0\)\
\-\ ohgaki\\:\\ 0\\.045917226893149435\ \(0\)\
\-\ lin\\:\\ 0\\.045917226893149435\ \(0\)\
\-\ ross\\:\\ 0\\.045917226893149435\ \(0\)\
\-\ similar\\:\\ 0\\.04580217818115476\ \(0\)\
\-\ for\\:\\ 0\\.045536332720375224\ \(0\)\
\-\ gbms\\:\\ 0\\.0444018568861264\ \(0\)\
\-\ interpret\\:\\ 0\\.0444018568861264\ \(0\)\
\-\ mannitol\\:\\ 0\\.0444018568861264\ \(0\)\
\-\ shifts\\:\\ 0\\.0444018568861264\ \(0\)\
\-\ existence\\:\\ 0\\.0444018568861264\ \(0\)\
\-\ js\\:\\ 0\\.0444018568861264\ \(0\)\
\-\ neurorx\\:\\ 0\\.0444018568861264\ \(0\)\
\-\ confer\\:\\ 0\\.04322644459143489\ \(0\)\
\-\ compounds\\:\\ 0\\.04322644459143489\ \(0\)\
\-\ inexpensive\\:\\ 0\\.04322644459143489\ \(0\)\
\-\ dn\\:\\ 0\\.04322644459143489\ \(0\)\
\-\ chang\\:\\ 0\\.04322644459143489\ \(0\)\
\-\ astrocytic\\:\\ 0\\.042266062818442716\ \(0\)\
\-\ hunter\\:\\ 0\\.042266062818442716\ \(0\)\
\-\ typically\\:\\ 0\\.042187810219788194\ \(0\)\
\-\ 50\\:\\ 0\\.041969298006275434\ \(0\)\
\-\ being\\:\\ 0\\.04187701975840829\ \(0\)\
\-\ location\\:\\ 0\\.04184643909075818\ \(0\)\
\-\ understand\\:\\ 0\\.04145407159917204\ \(0\)\
\-\ ef\\:\\ 0\\.04145407159917204\ \(0\)\
\-\ bd\\:\\ 0\\.04145407159917204\ \(0\)\
\-\ composition\\:\\ 0\\.040750692811419686\ \(0\)\
\-\ correctly\\:\\ 0\\.040750692811419686\ \(0\)\
\-\ technology\\:\\ 0\\.040750692811419686\ \(0\)\
\-\ sr\\:\\ 0\\.040750692811419686\ \(0\)\
\-\ instance\\:\\ 0\\.04013026875075903\ \(0\)\
\-\ turnover\\:\\ 0\\.04013026875075903\ \(0\)\
\-\ acta\\:\\ 0\\.04013026875075903\ \(0\)\
\-\ suppress\\:\\ 0\\.03957528051672818\ \(0\)\
\-\ creates\\:\\ 0\\.03957528051672818\ \(0\)\
\-\ noninvasive\\:\\ 0\\.03957528051672818\ \(0\)\
\-\ oncol\\:\\ 0\\.03957528051672818\ \(0\)\
\-\ often\\:\\ 0\\.039212413843905676\ \(0\)\
\-\ that\\:\\ 0\\.039118893617124825\ \(0\)\
\-\ examining\\:\\ 0\\.039073232590666834\ \(0\)\
\-\ indicator\\:\\ 0\\.039073232590666834\ \(0\)\
\-\ tumours\\:\\ 0\\.039073232590666834\ \(0\)\
\-\ frontal\\:\\ 0\\.03867917406533021\ \(0\)\
\-\ will\\:\\ 0\\.03867917406533021\ \(0\)\
\-\ pxa\\:\\ 0\\.038614898743736\ \(0\)\
\-\ neurocysticercosis\\:\\ 0\\.038614898743736\ \(0\)\
\-\ scant\\:\\ 0\\.038614898743736\ \(0\)\
\-\ 114\\:\\ 0\\.03819327247604523\ \(0\)\
\-\ clinical\\:\\ 0\\.038085803735700384\ \(0\)\
\-\ chosen\\:\\ 0\\.03780290752446532\ \(0\)\
\-\ utility\\:\\ 0\\.03780290752446532\ \(0\)\
\-\ dysembryoplastic\\:\\ 0\\.03743948644904449\ \(0\)\
\-\ elected\\:\\ 0\\.037099528736712975\ \(0\)\
\-\ sulcal\\:\\ 0\\.037099528736712975\ \(0\)\
\-\ changing\\:\\ 0\\.037099528736712975\ \(0\)\
\-\ years\\:\\ 0\\.03683783494320017\ \(0\)\
\-\ normal\\:\\ 0\\.0368049820393424\ \(0\)\
\-\ closer\\:\\ 0\\.03678018755286796\ \(0\)\
\-\ physicians\\:\\ 0\\.03678018755286796\ \(0\)\
\-\ hemispheric\\:\\ 0\\.03678018755286796\ \(0\)\
\-\ lactate\\:\\ 0\\.03647910467605232\ \(0\)\
\-\ request\\:\\ 0\\.03647910467605232\ \(0\)\
\-\ efficacy\\:\\ 0\\.03647910467605232\ \(0\)\
\-\ uses\\:\\ 0\\.036194304706496386\ \(0\)\
\-\ region\\:\\ 0\\.03594650708743171\ \(0\)\
\-\ astrocytomas\\:\\ 0\\.03592411644202146\ \(0\)\
\-\ assist\\:\\ 0\\.03592411644202146\ \(0\)\
\-\ upward\\:\\ 0\\.03592411644202146\ \(0\)\
\-\ xanthoastrocytoma\\:\\ 0\\.03566711345678164\ \(0\)\
\-\ mechanisms\\:\\ 0\\.03566711345678164\ \(0\)\
\-\ creating\\:\\ 0\\.03566711345678164\ \(0\)\
\-\ not\\:\\ 0\\.03558650508868059\ \(0\)\
\-\ suppression\\:\\ 0\\.035422068515960116\ \(0\)\
\-\ neuroepithelial\\:\\ 0\\.035422068515960116\ \(0\)\
\-\ recur\\:\\ 0\\.035422068515960116\ \(0\)\
\-\ louis\\:\\ 0\\.035422068515960116\ \(0\)\
\-\ turn\\:\\ 0\\.035187918131874434\ \(0\)\
\-\ been\\:\\ 0\\.03501241170951612\ \(0\)\
\-\ pathologically\\:\\ 0\\.03496373466902929\ \(0\)\
\-\ nervous\\:\\ 0\\.03496373466902929\ \(0\)\
\-\ progressing\\:\\ 0\\.03474870414732995\ \(0\)\
\-\ conducted\\:\\ 0\\.03474870414732995\ \(0\)\
\-\ prospective\\:\\ 0\\.03474870414732995\ \(0\)\
\-\ lobe\\:\\ 0\\.03472894081560374\ \(0\)\
\-\ mistaken\\:\\ 0\\.03454210840133852\ \(0\)\
\-\ history\\:\\ 0\\.03444003119282247\ \(0\)\
\-\ controversial\\:\\ 0\\.03434331060836863\ \(0\)\
\-\ physiologic\\:\\ 0\\.03434331060836863\ \(0\)\
\-\ high\\:\\ 0\\.03415443515691168\ \(0\)\
\-\ read\\:\\ 0\\.03415174344975861\ \(0\)\
\-\ supratentorial\\:\\ 0\\.03415174344975861\ \(0\)\
\-\ decision\\:\\ 0\\.03415174344975861\ \(0\)\
\-\ certain\\:\\ 0\\.033966899350522065\ \(0\)\
\-\ patients\\:\\ 0\\.03380709492915412\ \(0\)\
\-\ instead\\:\\ 0\\.03344836466200626\ \(0\)\
\-\ trial\\:\\ 0\\.03344836466200626\ \(0\)\
\-\ dnet\\:\\ 0\\.033286274448276434\ \(0\)\
\-\ more\\:\\ 0\\.032998944575712286\ \(0\)\
\-\ takes\\:\\ 0\\.03268361605809543\ \(0\)\
\-\ chemical\\:\\ 0\\.03268361605809543\ \(0\)\
\-\ preoperative\\:\\ 0\\.03268361605809543\ \(0\)\
\-\ eg\\:\\ 0\\.03201594938207492\ \(0\)\
\-\ already\\:\\ 0\\.03189200210332429\ \(0\)\
\-\ neonatal\\:\\ 0\\.031770904441253404\ \(0\)\
\-\ variety\\:\\ 0\\.031770904441253404\ \(0\)\
\-\ decade\\:\\ 0\\.03165252830665409\ \(0\)\
\-\ 4cm\\:\\ 0\\.03165252830665409\ \(0\)\
\-\ tissue\\:\\ 0\\.03152482827764831\ \(0\)\
\-\ locations\\:\\ 0\\.03142346977052802\ \(0\)\
\-\ other\\:\\ 0\\.03120864065128411\ \(0\)\
\-\ unfortunately\\:\\ 0\\.030993229410477555\ \(0\)\
\-\ infiltrative\\:\\ 0\\.030790607649060924\ \(0\)\
\-\ creatinine\\:\\ 0\\.030595492146561893\ \(0\)\
\-\ indicate\\:\\ 0\\.030595492146561893\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.03040734656410599\ \(0\)\
\-\ according\\:\\ 0\\.030225690069386718\ \(0\)\
\-\ look\\:\\ 0\\.030225690069386718\ \(0\)\
\-\ various\\:\\ 0\\.030050089932108472\ \(0\)\
\-\ making\\:\\ 0\\.030050089932108472\ \(0\)\
\-\ scale\\:\\ 0\\.029964437373304002\ \(0\)\
\-\ experience\\:\\ 0\\.029880155314391234\ \(0\)\
\-\ effacement\\:\\ 0\\.02979720058729954\ \(0\)\
\-\ 2007\\:\\ 0\\.029715532031940294\ \(0\)\
\-\ smith\\:\\ 0\\.029715532031940294\ \(0\)\
\-\ infiltration\\:\\ 0\\.029635110373569716\ \(0\)\
\-\ growing\\:\\ 0\\.02947785940345453\ \(0\)\
\-\ whether\\:\\ 0\\.02940095998948403\ \(0\)\
\-\ survival\\:\\ 0\\.029325167080360384\ \(0\)\
\-\ variable\\:\\ 0\\.029176776526638887\ \(0\)\
\-\ make\\:\\ 0\\.029176776526638887\ \(0\)\
\-\ improve\\:\\ 0\\.029176776526638887\ \(0\)\
\-\ after\\:\\ 0\\.0291533894206872\ \(0\)\
\-\ glucose\\:\\ 0\\.02903245198338871\ \(0\)\
\-\ pilocytic\\:\\ 0\\.02882311915429904\ \(0\)\
\-\ occasionally\\:\\ 0\\.02882311915429904\ \(0\)\
\-\ continues\\:\\ 0\\.02868804723296778\ \(0\)\
\-\ nuclear\\:\\ 0\\.028427870088967216\ \(0\)\
\-\ representing\\:\\ 0\\.028427870088967216\ \(0\)\
\-\ late\\:\\ 0\\.028364785307368207\ \(0\)\
\-\ better\\:\\ 0\\.028364785307368207\ \(0\)\
\-\ also\\:\\ 0\\.028267275787128888\ \(0\)\
\-\ corresponding\\:\\ 0\\.02811974036654669\ \(0\)\
\-\ cns\\:\\ 0\\.028060219775018064\ \(0\)\
\-\ degrees\\:\\ 0\\.028060219775018064\ \(0\)\
\-\ adults\\:\\ 0\\.028060219775018064\ \(0\)\
\-\ neoplasms\\:\\ 0\\.028001364231947375\ \(0\)\
\-\ neuro\\:\\ 0\\.028001364231947375\ \(0\)\
\-\ determine\\:\\ 0\\.02794315903967744\ \(0\)\
\-\ anatomic\\:\\ 0\\.027885589982461004\ \(0\)\
\-\ neural\\:\\ 0\\.027828643305620317\ \(0\)\
\-\ alcohol\\:\\ 0\\.0277723056958213\ \(0\)\
\-\ adult\\:\\ 0\\.027716564262391444\ \(0\)\
\-\ conditions\\:\\ 0\\.02744637599791652\ \(0\)\
\-\ bright\\:\\ 0\\.027393962467916755\ \(0\)\
\-\ enhance\\:\\ 0\\.026896657915705023\ \(0\)\
\-\ shift\\:\\ 0\\.026398925857401757\ \(0\)\
\-\ states\\:\\ 0\\.026398925857401757\ \(0\)\
\-\ degree\\:\\ 0\\.026270963703225007\ \(0\)\
\-\ major\\:\\ 0\\.026270963703225007\ \(0\)\
\-\ incidence\\:\\ 0\\.02586557016426369\ \(0\)\
\-\ decrease\\:\\ 0\\.025826695328747814\ \(0\)\
\-\ glioma\\:\\ 0\\.025525612451932172\ \(0\)\
\-\ by\\:\\ 0\\.025520102287460822\ \(0\)\
\-\ generally\\:\\ 0\\.02545295590271306\ \(0\)\
\-\ medications\\:\\ 0\\.025206271268087155\ \(0\)\
\-\ represent\\:\\ 0\\.02500364950667052\ \(0\)\
\-\ difficult\\:\\ 0\\.024937804695506636\ \(0\)\
\-\ their\\:\\ 0\\.024937804695506636\ \(0\)\
\-\ needed\\:\\ 0\\.024808534004171493\ \(0\)\
\-\ recurrence\\:\\ 0\\.024808534004171493\ \(0\)\
\-\ additionally\\:\\ 0\\.024745069184600812\ \(0\)\
\-\ neurological\\:\\ 0\\.024682359916550642\ \(0\)\
\-\ life\\:\\ 0\\.024651283034056302\ \(0\)\
\-\ pathologic\\:\\ 0\\.024620388421715586\ \(0\)\
\-\ relatively\\:\\ 0\\.024468576291839975\ \(0\)\
\-\ function\\:\\ 0\\.024321017166784722\ \(0\)\
\-\ compared\\:\\ 0\\.024291994964970726\ \(0\)\
\-\ increase\\:\\ 0\\.024121141621114593\ \(0\)\
\-\ 35\\:\\ 0\\.024093197172000837\ \(0\)\
\-\ 45\\:\\ 0\\.024093197172000837\ \(0\)\
\-\ 90\\:\\ 0\\.024010242444909142\ \(0\)\
\-\ there\\:\\ 0\\.023911876290015892\ \(0\)\
\-\ many\\:\\ 0\\.023690901261064125\ \(0\)\
\-\ tissues\\:\\ 0\\.023690901261064125\ \(0\)\
\-\ pathology\\:\\ 0\\.023588616177218375\ \(0\)\
\-\ with\\:\\ 0\\.02353496275577302\ \(0\)\
\-\ 80\\:\\ 0\\.023438818889263913\ \(0\)\
\-\ results\\:\\ 0\\.023414261659219348\ \(0\)\
\-\ free\\:\\ 0\\.023389818384248487\ \(0\)\
\-\ measuring\\:\\ 0\\.023245493840998315\ \(0\)\
\-\ complex\\:\\ 0\\.02315142855019227\ \(0\)\
\-\ attenuation\\:\\ 0\\.02299075110737182\ \(0\)\
\-\ mass\\:\\ 0\\.022954937546572036\ \(0\)\
\-\ ct\\:\\ 0\\.022878981683242237\ \(0\)\
\-\ at\\:\\ 0\\.022698891270384977\ \(0\)\
\-\ midline\\:\\ 0\\.022598771591394885\ \(0\)\
\-\ used\\:\\ 0\\.02249487243788612\ \(0\)\
\-\ incidental\\:\\ 0\\.022273261632627665\ \(0\)\
\-\ course\\:\\ 0\\.02219493280932326\ \(0\)\
\-\ greater\\:\\ 0\\.022136941218411973\ \(0\)\
\-\ tumors\\:\\ 0\\.0220986318400706\ \(0\)\
\-\ 40\\:\\ 0\\.0220986318400706\ \(0\)\
\-\ metastasis\\:\\ 0\\.022022838930946954\ \(0\)\
\-\ abnormality\\:\\ 0\\.02185619007019608\ \(0\)\
\-\ breast\\:\\ 0\\.021819862227560303\ \(0\)\
\-\ including\\:\\ 0\\.021503716382790555\ \(0\)\
\-\ they\\:\\ 0\\.021469732288757523\ \(0\)\
\-\ malignant\\:\\ 0\\.021419163743869818\ \(0\)\
\-\ intensity\\:\\ 0\\.021335946905649068\ \(0\)\
\-\ kidney\\:\\ 0\\.021109699773314627\ \(0\)\
\-\ liver\\:\\ 0\\.020728381653162556\ \(0\)\
\-\ benign\\:\\ 0\\.020640830890264014\ \(0\)\
\-\ elevated\\:\\ 0\\.020484005560834607\ \(0\)\
\-\ masses\\:\\ 0\\.020455986791027468\ \(0\)\
\-\ size\\:\\ 0\\.0203453787101941\ \(0\)\
\-\ cases\\:\\ 0\\.020210306788862837\ \(0\)\
\-\ central\\:\\ 0\\.02006562183944756\ \(0\)\
\-\ surrounding\\:\\ 0\\.020039737186357414\ \(0\)\
\-\ right\\:\\ 0\\.01992419753252598\ \(0\)\
\-\ known\\:\\ 0\\.019453854339985845\ \(0\)\
\-\ any\\:\\ 0\\.019419313125696756\ \(0\)\
\-\ while\\:\\ 0\\.019419313125696756\ \(0\)\
\-\ 20\\:\\ 0\\.019384996937201925\ \(0\)\
\-\ aspect\\:\\ 0\\.019384996937201925\ \(0\)\
\-\ image\\:\\ 0\\.019216691364280124\ \(0\)\
\-\ age\\:\\ 0\\.0188643248916659\ \(0\)\
\-\ t1\\:\\ 0\\.018721675500696994\ \(0\)\
\-\ see\\:\\ 0\\.01869160396533884\ \(0\)\
\-\ year\\:\\ 0\\.018520298982578138\ \(0\)\
\-\ month\\:\\ 0\\.01827844204529433\ \(0\)\
\-\ when\\:\\ 0\\.018150627753299634\ \(0\)\
\-\ appearance\\:\\ 0\\.018114671871000416\ \(0\)\
\-\ following\\:\\ 0\\.018025841497673122\ \(0\)\
\-\ head\\:\\ 0\\.017921185413296816\ \(0\)\
\-\ edema\\:\\ 0\\.017921185413296816\ \(0\)\
\-\ all\\:\\ 0\\.01788675707959799\ \(0\)\
\-\ include\\:\\ 0\\.017878185041409998\ \(0\)\
\-\ time\\:\\ 0\\.017810106338650274\ \(0\)\
\-\ 10\\:\\ 0\\.01757044465461211\ \(0\)\
\-\ if\\:\\ 0\\.017458535698607912\ \(0\)\
\-\ enhancement\\:\\ 0\\.01729500764774508\ \(0\)\
\-\ due\\:\\ 0\\.017272055470672378\ \(0\)\
\-\ cm\\:\\ 0\\.01725680939257874\ \(0\)\
\-\ one\\:\\ 0\\.01720379296498142\ \(0\)\
\-\ common\\:\\ 0\\.017040561088813164\ \(0\)\
\-\ signal\\:\\ 0\\.01703326030274623\ \(0\)\
\-\ over\\:\\ 0\\.016707914295495715\ \(0\)\
\-\ increased\\:\\ 0\\.016248437448385927\ \(0\)\
\-\ into\\:\\ 0\\.015972908945676295\ \(0\)\
\-\ man\\:\\ 0\\.015907694067277645\ \(0\)\
\-\ without\\:\\ 0\\.01584910040077884\ \(0\)\
\-\ imaging\\:\\ 0\\.015791151342145582\ \(0\)\
\-\ tumor\\:\\ 0\\.015716758240400155\ \(0\)\
\-\ most\\:\\ 0\\.015637800414861524\ \(0\)\
\-\ small\\:\\ 0\\.015499682478409523\ \(0\)\
\-\ may\\:\\ 0\\.015121015324895053\ \(0\)\
\-\ demonstrates\\:\\ 0\\.01509570284800697\ \(0\)\
\-\ had\\:\\ 0\\.014970933483214236\ \(0\)\
\-\ presents\\:\\ 0\\.014454557044260559\ \(0\)\
\-\ treatment\\:\\ 0\\.014313375626982176\ \(0\)\
\-\ seen\\:\\ 0\\.01414627488396134\ \(0\)\
\-\ which\\:\\ 0\\.01366304708065102\ \(0\)\
\-\ as\\:\\ 0\\.0120712795589103\ \(0\)\
\-\ left\\:\\ 0\\.01024997001960168\ \(0\)\
\-\ old\\:\\ 0\\.008892948991932959\ \(0\)\
